SOURCE: BioTech Medics, Inc.

April 17, 2007 09:00 ET

BioTech Medics Moving Charles R. Crane MD Pain Management Offices

DALLAS, TX -- (MARKET WIRE) -- April 17, 2007 -- BioTech Medics, Inc. (PINKSHEETS: BTMD) has announced that their Dallas Pain Management & Wellness Center will be moving to a new location as of May 1, 2007.

The offices of Charles R. Crane, MD will be moving to The Waterview Office Complex, 9535 Forest Lane, Suite 123, Dallas, TX 75243. Dr. Crane is a specialist in physical medicine and pain management. The new location has been completely renovated and will offer patients the added convenience of free covered underground parking.

BioTech Medics manufactures and sells Class IIIB Medical Therapeutic Lasers which have FDA 510(k) clearance. The lasers are for the reduction of muscular, skeletal and/or arthritic pain without surgery or drugs. BTMD has 3 affiliated Pain Management Centers located in Albuquerque, Overland Park, KS and Los Angeles. More are pending.

The Company developed and sells the SHBAN™ 3 oz. Go Anywhere Hand Sanitizer which has been clinically proven to kill the Avian Bird Flu and other viruses upon contact without harming humans, animals and the environment.

The clear superiority of SHBAN over other disinfectants is that SHBAN is longer lasting, as it leaves an invisible film on the hands. SHBAN does not evaporate after application compared to alcohol-based hand sanitizers. SHBAN is non-toxic (when used as directed), non-flammable, is non-bleaching with no toxic odor. Additionally, the SHBAN 3 oz. size is convenient to carry in a purse, briefcase, backpack, waist pouch or vehicle and passes the TSA Airport carry-on liquid requirements.

SHBAN is protected under US Letters of Patent #5,514,808, #5,574,050, #5,679,711 and #5,585,391. BioTech Medics will provide SHBAN samples to government or world health officials should they desire to independently test the SHBAN solution.

Pain Management & Wellness Center affiliations are available as well as SHBAN distributorships. Contact the company for applications.

Safe Harbor for Forward-Looking Statements.

This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. The FDA has not evaluated the SHBAN product. SHBAN is not for the diagnosis, treatment and/or cure of any disease. Void where prohibited.

Contact Information

  • Contact:
    BTMD Investor Relations